XML 54 R39.htm IDEA: XBRL DOCUMENT v3.21.2
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended
Jan. 08, 2021
Dec. 31, 2019
Apr. 19, 2019
Dec. 31, 2018
Jun. 30, 2021
Mar. 31, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
May 31, 2021
Mar. 08, 2021
Sep. 30, 2020
Feb. 27, 2020
Feb. 20, 2020
Allowance for doubtful accounts         $ 29,629     $ 29,629       $ 20,664    
Contingent liability         6,348,896     6,348,896            
Decrease (increase) of contingent liability         6,871,000   $ (7,580,000) (10,500,000) $ 30,580,000          
PPP loan               0 1,456,100          
Gain (loss) on extinguishment of debt         1,466,113   $ 0 1,466,113 $ 0          
FDIC amount               250,000            
Cash, Uninsured Amount         $ 18,440,072     18,440,072       $ 14,287,810    
Decrease in contingent liabilities description         The primary catalyst for the $2,100,000 decrease in contingent liabilities is the change in the Company’s common share price between March 31, 2021 to June 30, 2021 from $4.14 per share to $2.90 per share.                  
Receivable from payment processors               $ 342,713            
Increase Decrease in value of shares           $ 3,100,012                
Common stock shares issuable 5,000,000   2,000,000                      
Earnout shares issued                   562,278 3,348,520     5,127,792
Common stock shares issued         56,973,815     56,973,815       52,130,870    
Cure Based Development [Member] | First marking period [Member]                            
Fair value of shares issued     $ 53,215,163                   $ 4,620,000  
Increase Decrease in value of shares   $ 6,924,503                        
Common stock shares issuable       15,250,000                    
Unrestricted voting right shares       8,750,000                    
Earnout shares issuable       15,250,000                    
Earnout shares issued                     3,348,520   5,127,792  
Common stock shares issued     15,250,000                      
Cure Based Development [Member] | Second marking period [Member]                            
Fair value of shares issued                     $ 11,271,000   $ 4,620,000  
Increase Decrease in value of shares               $ 3,100,012            
Common stock shares issued                     3,348,520   5,127,792  
Cure Based Development [Member] | Third marking period [Member]                            
Fair value of shares issued                   $ 1,329,000        
Increase Decrease in value of shares               $ 522,104            
Common stock shares issued                   562,278        
Maximum [Member]                            
Merchant processing fee               5.00%            
Minimum [Member]                            
Merchant processing fee               3.00%            
Manufacturing equipment [Member]                            
Estimated useful life               five years            
Automobiles [Member]                            
Estimated useful life               three years